Price
694.1
+2.95%52W Range
Market Cap
₹6,964.65 Cr
Traded: ₹10.61 Cr (0.15%) 0.0x
Free Float: ₹1,305.18 Cr (0.81% of FF traded)
Volume · 60D trend
1.56 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | -- | +34.0% | -- | +34.0% | Stable |
| Profit | -- | -- | +72.0% | -- | +89.0% | Accelerating |
| Return | -- | -- | -- | -- | -- | -- |
| ROE | -- | +4.0% | +7.0% | -- | -- | Accelerating |
Quarterly Results
Jun 2025
Mar 2025
Dec 2024
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales | 282 | 266 | 260 | 246 | 228 | 219 | 197 |
| Expenses | 221 | 215 | 199 | 182 | 180 | 168 | 153 |
| Operating Profit | 60 | 51 | 61 | 64 | 48 | 51 | 44 |
| OPM % | 21.0% | 19.0% | 23.0% | 26.0% | 21.0% | 23.0% | 22.0% |
| Other Income | 7 | 12 | 3 | 4 | 7 | 4 | 5 |
| Interest | 2 | 3 | 6 | 45 | 6 | 6 | 5 |
| Depreciation | 25 | 26 | 22 | 23 | 20 | 19 | 18 |
| Profit Before Tax | 41 | 33 | 36 | -1 | 29 | 30 | 26 |
| Tax % | 22.0% | 9.0% | 11.0% | 1427.0% | 17.0% | 17.0% | 24.0% |
| Net Profit | 32 | 30 | 32 | -9 | 24 | 25 | 20 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 3.2 | 3.0 | 3.2 | -5.2 | 13.1 | 119.3 | 96.5 |
| Sales Growth (YoY) | 23.7% | 21.2% | 31.7% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -- | 2.3% | 5.7% | 12.3% | -- | 11.2% | -- |
| OP Growth (YoY) | 25.0% | 0.0% | 38.6% | -- | -- | -- | -- |
| OP Growth (QoQ) | 17.6% | -16.4% | -4.7% | 33.3% | -5.9% | 15.9% | -- |
| Profit Growth (YoY) | 34.9% | 22.1% | 60.3% | -- | -- | -- | -- |
| EPS Growth (YoY) | -- | -97.5% | -96.7% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | -5.6% | 161.3% | -104.4% | -- | 23.6% | -- |
| OP Margin | -- | 19.2% | 23.5% | 26.0% | -- | 23.3% | 22.3% |
| Net Margin | -- | 11.3% | 12.3% | -3.7% | -- | 11.4% | 10.2% |
| Material Cost % | -- | 22.4% | 22.5% | 22.1% | -- | 24.4% | 25.0% |
| Employee Cost % | -- | 17.3% | 16.6% | 17.5% | -- | 15.6% | 16.7% |
| P/S | 6.61 | 7.21 | -- | -- | -- | -- | -- |
| P/E | 165.66 | 5.92 | -- | -- | -- | -- | -- |
| P/B | 6.24 | 6.40 | 9.09 | -- | -- | -- | -- |
Exchange Filings
50Please find enclosed herewith Transcripts for the investors Earning call held on August 12, 2026.
Pursuant to Reg 30 of SEBI Listing Regulations, we hereby inform that Nephrocare Health Services, Phillipines Inc., a step-down wholly-owned subsidiary of the Company has acquired a dialysis ....
Declartion of voting results along with scrutinizers report of the 17th AGM of the Company.
Pursuant to Reg 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an investor conference call as per the disclosure annexed herewith.
Pursuant to Reg 30 of SEBI Listing Regulations, we hereby inform that Nephrocare Health Services, Phillipines Inc., an overseas stepdown wholly-owned subsidiary of the Company has acquired ....
Clarification to disclosure under Reg 30 dated May 26, 2026 regarding incorporation of Nephrocare Services Kazakhstan LLP.
Summary of proceedings of the 17th AGM of the Company.
In Continuation to our letter dated July 24, 2026 please find enclosed link of the audio recording of the Investors'' Conference Call held on August 12, 2026 on the Unaudited Standalone ....
Pursuant to Reg 32 of SEBI Listing Regulations, read with Reg 41 of SEBI ICDR Regulations, please find enclosed herewith Monitoring Agency Report for quarter ended June 30, 2026.
Please find attached the outcome of Board meeting held on August 11, 2026.
Press release on Un-audited standalone and consolidated financial results for the quarter ended June 30, 2026.
Please find attached investor presentation for quarter ended June 30, 2026.
Un-audited standalone and consolidated financial results for the quarter ended June 30, 2026.
Pursuant to Regulation 30 of SEBI Listing Regulations, we hereby inform you that the Company has scheduled an Investor Conference Call as per the disclosure enclosed herewith.
Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an Investor Result Conference Call on Wednesday, 12th August, 2026 at 10:00 ....
Nephrocare Health Services Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11-08-2026 ,inter alia, to consider and approve the Unaudited Standalone ....
Newspaper Publication regarding Notice on 17th Annual General Meeting and information on remote e-voting.
Annual Report for the FY 2025-26 including Notice of the 17th Annual General Meeting of the Company.
Dispatch of letter providing a web-link of the Annual Report for the FY 2025-26 along with AGM notice.
Notice of 17th Annual General Meeting of the Company to be held on Wednesday, August 12, 2026.
Newspaper publication titled 17th Annual General Meeting of the Company through Video conferencing / Other Audio Visual Means, Cut-Off date information.
Pursuant to Reg 30 of SEBI Listing Regulations, 2015, we hereby inform that the Company has approved allotment of 2,18,297 equity shares of face value of Rs. 2/- each, pursuant to the exercise ....
We are enclosing herewith a certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for quarter ended 30th June, 2026 received from M/s. KFIN Technologies Limited.
This is to inform that the company has provided collateral/security support by issuance of SBLC as per the details disclosed herewith.
This is to inform that the Company has issued a Corporate Guarantee and provided collateral/security support as per the details annexed disclosed herewith.
Pursuant to Reg 30 of SEBI LODR Regulations, 2015, we hereby inform that Nephrocare Health Services, philippines Inc., overseas step-down wholly owned subsidiary of the company has acquired ....
Pursuant to Reg 30 of SEBI LODR Regulations, 2015, we hereby inform that Nephrocare Health Services, Philippines Inc., overseas step-down wholly owned subsidiary of the company has acquired ....
Pursuant to Regulation 30 of SEBI LODR, 2015, we hereby inform you that the Company has approved the NephroPlus Employee Stock option scheme 2026 in the Board meeting held on June 22, 2026 ....
Trading window shall be closed till 48 hours from the declaration of the Unaudited Financial Results of the Company for the quarter ended June 30, 2026.
In reference to our letter dated May 27, 2026, regarding Analyst Meet has now been cancelled due to unavoidable exigencies as per disclosure annexed herewith.
Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an Investor Conference Call as per the disclosure enclosed herewith.
Pursuant to Reg 30 of SEBI LODR Regulations, 2015, we hereby inform that Nephrocare Health Services, Philippines Inc., overseas step-down wholly owned subsidiary of the company has acquired ....
Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an Investor Conference Call as per the disclosure enclosed herewith
Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an Investor Conference Call as per the disclosure enclosed herewith.
Please find enclosed herewith Transcript for the Investor Earnings Call held on May 20, 2026.
Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an Investor Conference Call as per the disclosure enclosed herewith.
Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an Investor Conference Call as per the disclosure enclosed herewith.
Pursuant to Reg 30 of SEBI LODR Regulations, 2015, we hereby inform that Nephrocare Health Services, Philippines Inc., overseas stepdown wholly owned subsidiary of the Company has acquired ....
Pursuant to Reg 30 of SEBI LODR Regulations, 2015, we hereby inform that Nephrocare Health Services International Pte. Ltd, overseas wholly owned subsidiary of the Company has incorporated ....
Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an Investor Conference Call on Tuesday, June 2, 2026 at 11:00 AM (Indian Standard Time).
In continuation to our letter dated May 04, 2026, please find enclosed link of the audio recording of the Investors' Conference Call held on May 20, 2026 on the Audited Standalone and Consolidated ....
The Board of Directors of the Company at its meeting held today, i.e., Tuesday, May 19, 2026, inter-alia, considered and approved Audited Standalone and Consolidated Financial Results of ....
Press Release on Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026.
Please find attached herewith Investor Presentation for quarter and year ended March 31, 2026.
This is to inform you that the Board of Directors in its meeting held on has approved and granted in-principal approval for providing corporate guarantee as per the disclosure annexed herewith.
The Board of Directors at its meeting held on May 19, 2026 has re-appointed M/s. BDO India LLP as Internal Auditor as per the disclosure annexed herewith.
Pursuant to Reg 32 of SEBI LODR Regulations, 2015 read with Reg 41 of SEBI ICDR Regulations, 2018, please find enclosed Monitoring Agency Report for quarter ended March 31, 2026.
Pursuant to Reg 30 of SEBI LODR Regulations, 2015, we hereby inform that Nephrocare Health Care Services, Philippines, Inc., step-down wholly owned subsidiary of the Company has acquired ....
Nephrocare Health Services Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2026 ,inter alia, to consider and approve the Audited Standalone ....
Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby inform you that the Company has scheduled an Investor Result Conference Call on Wednesday, 20th May, 2026 at 16:00 IST ....
Credit Ratings
3Concalls
1Feb 2026
28 Feb 2026Held by ETFs
1 ETFs hold NEPHROPLUS · sorted by weight
Held by Mutual Funds
9 schemes hold NEPHROPLUS · sorted by weight